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Abstract The UK DNA Banking Network (UDBN)
is a secondary biobank: it aggregates and manages
resources (samples and data) originated by others. The
network comprises, on the one hand, investigator
groups led by clinicians each with a distinct disease
specialism and, on the other hand, a research infra-
structure to manage samples and data. The infra-
structure addresses the problem of providing secure
quality-assured accrual, storage, replenishment and
distribution capacities for samples and of facilitating
access to DNA aliquots and data for new peer-
reviewed studies in genetic epidemiology. ‘Fair
access’ principles and practices have been pragmat-
ically developed that, unlike open access policies
in this area, are not cumbersome but, rather, are ﬁt
for the purpose of expediting new study designs
and their implementation. UDBN has so far distrib-
uted [60,000 samples for major genotyping studies
yielding[10 billion genotypes. It provides a working
model that can inform progress in biobanking nation-
ally, across Europe and internationally.
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Introduction
New experimental approaches in genetic epidemiol-
ogy such as genome wide association (GWA) studies
have been developed successfully in recent years.
These studies seek to identify the multiple loci which
each contribute to genetic risk for a given disease. As
these studies progress, they require ever larger
numbers of cases and appropriate controls (Davey
Smith et al. 2005) with greater accuracy in sample
management and deeper and more precise phenotypic
information.
Identifying the required numbers is usually only
possible by researchers collaborating together. How-
ever, after identifying where in the world such
numbers exist, a major logistics problem of collection
aggregation has to be solved. To address this problem
in genetic epidemiology, managing and overseeing
access to samples and data has become a specialism
undertaken by a dedicated research infrastructure: the
biobank. Few research laboratories have the culture,
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work. Biobanking encompasses the activities of an
investigation that occur after study design and before
data analysis. It involves processing samples and
managing data in a secure, quality-assured environ-
ment. To optimise collaboration and efﬁciently drive
the discovery process, funders and researchers alike
are looking to use secondary biobanks—biobanks
that manage resources originated by others.
The UK DNA Banking Network (UDBN www.
dna-network.ac.uk) is such a biobank and is presented
here as a case study of good practises. The research
infrastructure has evolved to provide secure quality-
assured accrual of resource, storage, replenishment
and distribution of samples, supporting the movement
of DNA aliquots and data for the purposes of new
peer-reviewed studies in genetic epidemiology.
Here we outline the preparatory phase of the
biobanking network; describe policies associated with
thenetworkandpoliciesonthereceiptanddistribution
of samples and data; summarise how sample and data
managementisundertakenandqualityiscontrolled;and
drawsomeconclusions.
Preparatory phase
In its 1999–2003 strategic plans, the UK Medical
Research Council (MRC) decided to ‘‘develop new
collections of DNA samples with associated pheno-
typic, health and environmental information, as a
unique national resource for research into multifac-
torial disease’’ (Plan 1999). £12 million had been
earmarked for this unique initiative, which MRC
wished to develop in conjunction with the UK charity
sector and the National Health Service.
In 2000, MRC issued a Call for Proposals entitled
‘‘Establishing a UK network for DNA sample banking
and genotyping’’. This identiﬁed genetic epidemiol-
ogy as a ‘‘strategically important area for translating
knowledge of the human genome sequence into real
beneﬁts for human health’’. Its proposed national
biobanking network would for the ﬁrst time create a
research infrastructure—a biobank—to support
genetic epidemiology in general. Whereas genetic
epidemiology research infrastructure had hitherto
been supported for ‘primary biobanking’, in which a
researcher designs, accrues, manages and investigates
a resource, this was a plan for ‘secondary biobanking’
where resource management is undertaken centrally.
MRC envisaged a network of centres that would
house large DNA collections, manage associated
databases and make the resources (i.e. samples and
data) available to researchers. The initial collections
populating the network were in 14 high-impact
diseases (Table 1). One disease collection based
overseas was unable to join the network because local
law prohibited export of human DNA. These awards
Table 1 MRC collections
managed by UDBN
ICD, WHO International
Classiﬁcation of Disease
(v.10); FTA, DNA spotted
on Whatman FTA paper;
PBL, peripheral blood
lymphocytes; LCL,
lymphoblastoid cell lines
ICD block Collection Stock DNA FTA spot PBL LCL
C00-D48 Colorectal Ca 5,583 5,570
Breast Ca 227 0
E00-E90 Type 2 diabetes 800 0 2,845 1,286
F00-F99 Unipolar depression 1,063 0 1,324 112
G00-G99 Parkinson’s 462 462
Alzheimer’s 375 0 2,730 626
Multiple sclerosis 1,678 822 811 451
H00-H59 Age-related macular degeneration 1,696 0
I00-I99 Hypertension 864 3,584
Coronary heart disease 4,635 4,635 4,637 108
J00-J99 Asthma 863 0 850
L00-L99 Eczema 1,044 0 950
N00-N99 Glomerulonephritis 5,832 3,159 2,985 199
TOTALS 26,559 14,648 15,332 6,366 8,166
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to be managed ‘‘as shared national resources’’ and
‘‘made available to collaborators’’. Awardees were
‘‘required to transfer a portion of each sample’’ to the
network and ‘‘to add any genotype data they obtain to
the common database’’. These award conditions were
critical to the success of UDBN.
Looking to the future, MRC envisaged that further
collectionsinthenetworkmightbefundedeitherbythe
MRC itself or by other funders. It saw the network as
‘‘complementary’’ to and being ‘‘closely coordinated’’
with what was at that time an early stage proposal for a
healthy cohort study on 500,000 volunteers [now
known as the UK BioBank project(Ollier et al. 2005)].
Competitive bids to build UDBN were reviewed
by an international panel and support commenced in
2003 for three activities:
• Management of resources. DNA sample and data
management is undertaken at the Centre for
Integrated Genomic Medical Research (CIGMR)
in the University of Manchester. Cell manage-
ment is undertaken at the Health Protection
Agency’s European Cell and Culture Collection
(ECACC). Management of sample annotations
and UDBN’s interactive website is out-sourced to
a specialist bioinformatics consultancy.
• Management of access. Principles of access to
samples and data have been approved by an MRC-
appointed international Steering Committee that
has provided oversight to the project as a whole.
Terms of reference are summarised in Box A.
• Coordination of the biobanking network.
Policy and its development
The policies of a secondary biobank need to govern
receipt, storage and distribution of samples and data.
They should satisfy the interests of all stakeholders:
the patient or subject, the collector, the biobank, the
recipient of samples or data, the various funders and
institutions. Some of these interests are expressed in
current law. Others arise from the practicalities of
carrying out a study. Where interests conﬂict, coor-
dinating activities within the network of collectors
and infrastructure have assisted in arriving at com-
promise solutions. Working through these consider-
ations in a pragmatic fashion and recognising the
need for simple, cost effective solutions, UDBN has
rejected the unrestricted ‘open access’ model and has
developed a ‘fair access’ model. The principle of fair
access has been promulgated through the United
Nations Educational Scientiﬁc and Cultural Organi-
sation (UNESCO) International Declaration on
Human Genetic Data (2003) which provides that
states should regulate the ﬂow of data and samples
‘‘to ensure fair access’’ (http://portal.unesco.org/
en/ev.php-URL_ID=17720&URL_DO=DO_TOPIC&
URL_SECTION=201.html).
The principles of fair access on which UDBN
sought to develop its policies are listed in Box B.
Some comment is appropriate here:
• The central concern of researchers is control: who
controls access to samples and data? On this
question, UDBN opted simply to rely on an
existing type of relationship between researchers
that is as old as science itself: the relationship of
collaboration. This has the advantages of having
Box A UDBN management committee key terms of reference
To advise the local management committee on protocol
development, operational issues, risk management strategies
and good practice principles
To monitor applications to deposit and access DNA samples
To alert the Medical Research Council of any ethical or other
implications which may put the participants in the research,
the public and/or council at risk
Box B Principles of Fair Access
Fair to the subject (or patient)
Privacy and conﬁdentiality
Ethical use of samples and data
Consent management: national open methods to permit
effective withdrawal of consent
Public engagement: understanding and goal-setting
Fair to the collector
Exploration rights: right to sole access restricted
to speciﬁed experiments
Fair to the recipient
Collaboration management: to ensure transparency
Access to usable published/unpublished data
Long term availability of sample: long-term support and
replenishment of sample
Minimum of administration
Fair to collector’s and investigator’s institution
Intellectual property rights management: long term tracking
of samples, data, uses
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largely self-monitoring and of having proven
effectiveness and value. UDBN avoided the ideal
of ‘‘open access’’ wherein non-collaborators
could access samples and full data sets. Open
Access requires the creation of a cumbersome
oversight mechanism to minimise misuse of data.
This misuse can arise unintentionally: it could be
a consequence of the fact that biomedical data
categories have not been standardised. If the
biomedical research community were to agree a
common ontology, then it would be advisable to
consider this matter again. However, most future
collectors are likely to continue to introduce some
non-standard (i.e. experimental) biomedical data
categories into their accrual work. Such innova-
tion is essential and desirable but may allow
unintentional misuse of openly accessible bio-
medical data by a non-collaborating investigator.
The counter-argument to the problem of this
unintentional misuse is that peer review of the
resultant manuscript would discover the misuse.
However this counter-argument is ﬂawed unless
peer review is carried out by the collector. This
would then contradict the principle that peer
review should not be undertaken by a person with
a competing interest.
• National consent management is an ambition of
UDBN primarily because of the beneﬁts it can
provide to the subject. It would create a single
contact point where members of the public can go
if they wish to withdraw consent. For now, a
subject must recall precisely who consented them
for what. It also beneﬁts collectors by reducing
administrative burdens. A consent database needs
to be isolated, with linkage to other data sets only
permitted to a ‘consent guardian’. To realise this
ambition, substantial work needs to be undertaken
with all stakeholders.
• It is reasonable to assert the right of a collector to
exclusive access to his/her collection for the
purposes of the investigational goals stated in the
initial collection proposal. A collection proposal
with no stated investigational goals is unlikely to
attract support. A proposal with too many such
goals seems unfocussed and so is unlikely to
attract support. A collector who attains his initial
goals will be in the strongest possible position to
set the next goals—with or without collaborators.
This ‘ﬁrst mover’ advantage is inevitable and
probably desirable. Quashing that advantage with
an ‘open access’ policy seems undesirable
because of its possible demotivating effect.
• When an investigator seeks to collaborate with a
collector, anecdotal evidence suggests that the
relationship can come under stress. This can
endanger the security of shared conﬁdential data
as well as the joint investigation. By tracking
communications between the two parties, the
biobank encourages them to have a more trans-
parent relationship and is well-placed to mediate
if stresses arise.
Coordination of the network
The need for coordination and continuous dialogue
between, on the one hand, the 13 groups of inves-
tigators involved in making disease-speciﬁc collec-
tions and, on the other, the research infrastructure was
recognised at an early stage by one of the clinical
investigator groups. As a result, the MRC made
funding available speciﬁcally for networking meet-
ings. The case for networking was based on the fact
that a number of the investigator groups were already
funded for other collection activities by other funders
and so already had well-established procedures. This
case was strengthened by recognition of the rapidly
evolving research environment into which UDBN
was entering.
Inclusive and ﬂexible biannual network meetings
have therefore been held to facilitate the process of
integration of the collections at UDBN. Throughout,
each party has chosen freely whether to participate in
developments within the network. At times, when a
universal consensus view has been slow to emerge, a
system of phased integration has been used. This has
entailed early adoption, delayed adoption or even late
adoption of a proposed common practise. Participants
have thus been able to engage at a speed and in a
manner suited to their own particular needs. These
needs sometimes included the ability to observe the
effective engagement of others. This process has seen
a change from restrictive and competitive patterns of
academic behaviour to a pattern of broad and effective
collaboration as reﬂected, for example, in the success
of the Wellcome Case Control Consortium (2007)
seven of whose investigators hold collections in
UDBN facilities.
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Under the terms of their MRC awards, collectors were
required to deposit an aliquot of DNA at UDBN.
A Material Transfer Agreement (MTA) between
the collector’s institution and UDBN’s institution
(University of Manchester) was therefore appropriate.
Its main terms are shown—simpliﬁed—in Box C.
UDBN needs reassurance that all material was
collected ethically and needs information so that it
can act if advised of a subject’s withdrawal of consent.
The collector needs reassurance that UDBN will
implement a proper duty of care for the resource.
Data receipt at UDBN
Extensive discussions were held with collectors
leading to decisions that:
• Personal data (e.g. name, address, National Health
Service number) should not be held by UDBN.
The policy re-assures any collectors who might
retain concerns over theoretical breaches of
patient conﬁdentiality. For most collections,
UDBN has a sample identiﬁer but no personal
identiﬁer. This policy limits the closeness of
collaboration between a collector and a third party
researcher. It also delays development of centra-
lised consent management. Such management is
needed to increase the transparency of research
and thus maintain public trust. For some newer
collections, UDBN undertakes project manage-
ment during the accrual phase. This can require
UDBN to hold some personal information. How-
ever only appropriate, registered, named individ-
uals (e.g. Principal Investigators) can access this
information.
• Searchable summary data on 10 phenotype data
categories speciﬁed by each collector should be
made accessible to bona ﬁde researchers.
UDBN was built before GWA studies had been
initiated. However, it was clear that GWA data would
become a major resource and that the bioinformatics
challenge of managing this data should be addressed
by the community as a whole. UDBN is working with
Box C Material transfer agreement between collector and UDBN (simpliﬁed)
Depositor institution undertakings
The depositor institution agrees to:
Provide UDBN with the principal investigator’s successful proposal(s) seeking support to undertake the collection and with the
corresponding award letter(s) and terms and conditions of support
Provide UDBN with ethics committee approval(s) of the collection and the form(s) of consent to be signed by the subjects of the
collection
Afﬁrm that the consent form allows retention of samples in a place whose deﬁnition embraces UDBN and allows genetic
characterisation of the samples
Provide UDBN with the questionnaire(s) to the subjects of the collection and with a list describing the clinical and other
phenotypic tests performed
Delegate to the principal investigator the responsibility to enable appropriate access to information and data on the collection
Require the Principal Investigator to inform UDBN promptly of the unique identiﬁer of DNA material when the corresponding
subject is deemed by the principal investigator to have withdrawn consent described elsewhere
UDBN undertakings
UDBN agrees to:
Exercise a proper duty of care for the collection, taking all reasonable measures to ensure
Safekeeping and conservation of the DNA sample
Replenishment of the DNA sample to the extent that funds allow
Consistency between the information on the collection made available via UDBN and the information provided to UDBN by the
principal investigator and registered users
The conﬁdentiality of all items or types of unpublished information on the Collection speciﬁed by the principal investigator
Remove from the collection and take reasonable steps to destroy DNA material for a given subject when the principal investigator
deems that subject to have withdrawn consent
Promote on the UDBN website and in other media the appropriate use of the collection
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Genome-phenomeArchive(www.ebi.ac.uk/ega)onthis.
Data distribution
Figure 1 illustrates the steps that need to be taken by
a website user to access data and DNA aliquots from
UDBN.
Data are distributed via the project website (www.
dna-network.ac.uk) to third party researchers. Their
bona ﬁdes are established when a website user applies
online for registration. If successful, this yields a user
name and password to allow access to a restricted
area of the website. An applicant must supply their
personal workplace email address and the workplace
email address of their systems administrator. This
allows UDBN to verify the applicant’s association
with the workplace and then, separately, to establish
its nature. Any workplace that is not an academic
research body is carefully scrutinised. If the work-
place business were in the legal, insurance or law
enforcement ﬁeld, the application would be referred
to lawyers at UDBN’s host institution. Virtually
all applicants have been from European academic
institutions. Applicants from drug development
companies had previously established collaborations
directly with UDBN collectors.
Information about and summary data on each
collection is held in a relational database held on
UDBN’s secure server at the University of Man-
chester. The number of phenotype data items varies
between collections from four to 35. This is based
currently on data snapshots provided by collectors.
A search tool allows registered users—researchers—
to explore data sets and sub-sets. The researcher is
able to communicate online with the group of
collectors responsible for a collection to negotiate
and pursue collaboration. The communications are
logged to allow UDBN to provide an audit trial and
to permit UDBN to contribute to negotiations where
necessary.
After collaboration is agreed between a collector
and a researcher, it is likely that, in designing their
collaborative study, they will want to share data in
full, not just summary data. This is implemented by
UDBN giving the collector the ability to vary
permissions so that the named researcher may access
fuller data.
The current incomplete phenotype data sets on the
website are adequate for the purpose of third parties
who wish to initiate a collaboration. However, there
is in fact no risk to collectors associated with
presenting summary data on all their standard phe-
notypes. In the special case of novel phenotypes
devised by a collector, release of summary data can
be delayed until those phenotypes have been
described in a peer-reviewed journal. Such publica-
tion provides an adequate measure of quality assur-
ance for those novel phenotypes. If publication is to
trigger website data release, then good communica-
tions between the infrastructure and the collector
need to be maintained over an extended period. It is
important that collectors see secondary biobanking as
improving their access to new collaborations since, as
this is increasingly recognised, their motivation to
release all summary data sets increases. Therefore
networking events are necessary not only to establish
but also to maintain the scientiﬁc value of the
biobank.
The website registration system is of value
because it [a] acts to reassure collectors; [b] will
facilitate agreement on access to genotyping data
and; [c] will aid use of new tools that UDBN is
developing to streamline sample accrual. Fig. 1 Approval process for sample distribution
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Registered researchers can generate online a ‘‘wish
list’’ of samples that they want to test in collaboration
with a collector. Since the study they are planning
requires peer review and may require ethics approval,
the researcher and the collector need to prepare a
proposal (off line). This proposal will contain the
wish list and will identify the planned tests on those
samples.
UDBN requires a copy of the proposal so that its
Technical Access Committee (TAC) (a sub-commit-
tee of the MRC Steering Committee) can determine
whether the proposal is acceptable from a technical
point of view. TAC members consider nine questions
(Box D) aimed at ensuring that efﬁcient and high
quality work is planned; that renewable DNA sources
will be used where possible; that the resulting data
will in due course enrich the resource for other
investigations. After TAC approval, the wish list
becomes a ‘‘pick list’’ for the biobank’s Laboratory
Information Management System (see below). This
will then permit samples to be picked out of the
storage system. However no picking starts until the
biobank is informed of successful peer review and
ethics approval. If TAC ﬁnds the proposal unaccept-
able, the researcher and collector are informed and
biobank staff will help them modify their proposal to
address TAC’s concerns.
Before DNA sample picking starts, the recipients
are required to accept terms and conditions listed in
Box E. This ensures that DNA is used for the stated
purposes only and not for commercial gain; and that
UDBN will receive access to all genotype data at the
time of its publication.
UDBN is minded to modify this procedure to bring
it into line with UK BioBank. This infrastructure
plans directly to commission genotyping or other
tests speciﬁed by a researcher for an approved
investigation. In this way, data return to the infra-
structure is guaranteed and consistency of experi-
mental data quality can be assured.
Sample and data management
Sample management
Samples can be accepted at UDBN’s DNA laboratory
either as 7–10 ml EDTA blood samples or as DNA
aliquots in wells or tubes. On arrival, samples are
logged-in to UDBN’s Laboratory Information Man-
agement System (LIMS) using the collector-supplied
unique donor identiﬁer. The identiﬁer is typed in
twice and is compared with an external list of
identiﬁers from the collector. Blood samples are
extracted robotically using proprietary M-PVA Mag-
netic Beads (chemagen Biopolymer-Technologie)
and DNA is dispensed into 1.0 ml tubes (Griener).
DNA concentration estimation is performed using
emission spectrophotometry (FluoroSkan) run on a
Tecan Genesis Freedom 2000 automated liquid
handling workstation.
Dilution of stock to 100 ng/ul in 0.1 M Tris/
0.01 M EDTA pH 7.5 is performed using a Hamilton
Star liquid handling work station, after mixing using
a Microtec vortexer. 1D bar coded tube racks, ﬁtted
with lugs that prevent misleading, hold 96 2D bar
coded Matrix tubes and are stored in customised
freezers. Location data is captured using a hand-held
PDA device (Falcon; Unitech PT930S). Microsoft
Active Sync software automatically uploads location
data from the PDA to the host PC. -80 C freezers are
located in the University of Manchester. Second site
storage of an aliquot at the UK BioBank facility near
Manchester guards against catastrophic loss.
To withdraw an aliquot, racks are retrieved manu-
ally, tubes are picked using the BioMicroLab XL20
Tube Handler, thawed and mixed. Aliquots are
removed and dispensed using a liquid handling robot
to a speciﬁed tray format and layout. Volumes
Box D Issues addressed by technical access committee
The platform(s) is appropriate for the tests
There is no other platform available that uses substantially less
DNA
The out-sourced genotyper is reputable
The amount of DNA/sample requested matches the amount of
DNA/sample required
The requested concentration of DNA is reasonable for the
platform
The test(s) can be performed with comparable reliability on
cell line DNA or on WGA-DNA as on blood-derived DNA
Less than 20% of the tests on the samples requested have not
been performed or submitted for approval previously
The plan for data access is reasonable
The peer review processes of the funder are acceptable
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VolumeCheck. Trays are despatched on dry ice by
courier.
The LIMS used to track samples within the labo-
ratory is a fully customised installation of Nautilus
(version 8.1) (Thermo Fisher Scientiﬁc). It is based on
an Oracle 10 g database. The most basic in-house
customisation involved the creation of a workﬂow for
each type of sample to be received by the laboratory;
the workﬂow models the processes which may be
performedontheparticularsampletype.Additionalin-
house customisation provides validation and extra
functionalityusingInfomakerreports(Sybase),Oracle
PL/SQL and Microsoft Visual Basic 6 extensions.
The LIMS server makes use of a redundant array
of ﬁve independent disks. The redundancy ensures
that if a disk crashes, LIMS operation is not
disrupted. Data is safeguarded using a twenty tape
rotation tape backup strategy.
Phenotypes, genotypes and the website
The design of the database was the key issue when
developing the website. It needed to be ﬂexible
(because new phenotypes are being used) as well as
scalable for the large volumes of data expected. The
desire for the system to be ‘‘open source’’ for
academic institutions helped decide the technologies
that would be used.
The database was created using MySQL and when
each collection is added to the database, meta data is
created for each phenotype to aid processing and
comparison of the data items, both in terms of
ﬁltering within the collection and comparison with
other collections.
Java web services are used to process the data and
manage the workﬂow for collectors using the system,
which is all brought together with a content manage-
ment system written in PHP that then presents the
data and collaboration management features to users.
Using these technologies provides a highly ﬂexible
platform allowing easy integration to other systems
so that services that might exist elsewhere—as at
genotype databases—need not be ‘‘re-invented’’.
Quality control and assurance
All three infrastructure providers in UDBN imple-
ment ISO9001-2000. All procedures are speciﬁed in
standard operating procedures; all use of procedures is
monitored and all versions of procedures are tracked.
This ensures reproducibility. A condition of biannual
accreditation by the International Standards Organi-
sation is a programme of quality improvement. This
condition is, in its effects, a driver for undertaking
methods research. The decision to seek ISO accred-
itation for UDBN was based on the recognition that an
infrastructure should add value in resource manage-
ment in ways that conventional research laboratories
will not or cannot. The culture of a conventional
research laboratory encourages innovation at all
Box E Terms and conditions of release of DNA material
The Recipient may use the DNA material only in the common good
The Recipient shall not sell, transfer, release or distribute the DNA material to a third party or use the DNA material for proﬁt or any
other commercial gain
The Recipient agrees to only use the DNA material in the previously speciﬁed tests
The Recipient agrees to give UDBN access to all the data on all tests performed on the DNA Material within 10 days of the date of
publication of a paper reporting on any of the tests on any of the samples. Unjustiﬁed delay will lead to UDBN advising the funders
and the depositor institution of non-compliance
The Recipient agrees that UDBN may publish (at a time not before the date of publication of a paper that describes the results of the
speciﬁed tests) via the UDBN website
1. General information about the tests to the public
2. Summary data about the results to registered users of the UDBN website
3. De-identiﬁed subject-speciﬁc data about the results to registered users named by the recipient
The Recipient shall acknowledge UDBN as supplier of DNA from the relevant collection in all written or electronic reports and
publications
At the request of UDBN the recipient agrees to return or destroy any remaining DNA material at the end of the project
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seeks to manage innovation within a strict quality
control and assurance framework.
Methods research has been undertaken on a number
of processes, for example on DNA concentration
estimation. UDBN, in conjunction with Public Pop-
ulation Project in Genomics (P3G: www.p3gcon
sortium.org), has performed an observational study
on 14 academic and commercial laboratories for DNA
concentration estimation. This has quantitated the
errors in estimation that arise both within and between
labs that have hitherto been the subject of anecdotal
reports (ms in prep). UDBN, jointly with P3G and
with European partners in the pan-European Bio-
banking and BioMolecular Resources Infrastructure
initiative (BBMRI: www.biobanks.eu; Yuille et al.
2007) is now planning to identify and collaboratively
reduce common major sources of this error. This will
reduce costs and the long delays that are seen in large
studies after the required samples have been identiﬁed
and before genotyping has actually begun.
Discussion
UDBN has provided over 60,000 aliquots of the
40,000 samples that it manages for candidate gene
and GWA studies, including those conducted through
the Wellcome Trust Case Control Consortium (2007).
New collector groups are now working with and
seeking to work with UDBN on accrual management
as well as sample and data management for both
cross-sectional and longitudinal studies. Thus this
secondary biobank is resolving major bottlenecks in
genetic epidemiological investigation and accelerat-
ing progress in this ﬁeld. It is also reducing the need
for repeated investment in new infrastructure and
resource management, helping clinicians focus on
their core competencies in study design and paving
the way for future investigations based on shared
phenotypes, genotypes or other exposure.
The debates that have taken place within the
network and with colleagues in BBMRI and P3G
have led UDBN to formulate some principles of ‘fair
access’. They are pragmatic principles based on
existing practise. We suggest they meet the basic
needs of the genetic epidemiology community for
improved access not just to data but also to samples.
This is the key advantage of secondary biobanking
over data-sharing schemes such as the Genetic
Association Information Network (2007).
A summary of the advantages of secondary
biobanking is shown in Box F and below are
identiﬁed some of the main general lessons we have
learnt so far from building UDBN.
• Investment by funders in research infrastructure,
as distinct from buildings infrastructure, has not
been a priority for biomedical funders (Note that
in the physical sciences the distinction between
the two can be blurred—in astronomy one cannot
construct a large optical telescope without a
building to house it). UDBN’s resource manage-
ment requires small ﬂexible robots and data
networks. A good primary biobank may attract
support for this as part of a speciﬁc investigation.
However it was the vision of the beneﬁts of
secondary biobanking that persuaded MRC to
support UDBN. A critical aspect of this support
was the condition of support given to collectors
requiring them to provide samples to UDBN and
to lodge data in a common database. Without this
condition, UDBN would have had great difﬁculty
in overcoming fears about conﬁdentiality and
ownership that impede resource aggregation in
biomedical research.
Box F Advantages of secondary biobanking
Acts as an ‘honest broker’: its policies must be fair to investigators as depositors or recipients of samples or data
Ensures that a collection can outlive its originators
Facilitates extending studies (e.g. from cross-sectional to longitudinal)
Extends the useful life of a non-renewable resource. A primary biobanker has a powerful motivation to perform ‘‘just one more
experiment’’ on that resource
Offers and creates economies of scale
Offers advantages in resolving the ethical, legal and societal issues connected with biobanking
Provides an appropriate environment in which to conduct methods research to improve resource management
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123• Secondary biobanking has a structuring effect on
research. It manages all samples in a standard way
regardless of the investigation for which they
have been collected. The data that it aggregates,
while it may be deposited using different vocab-
ularies, is readily amenable for the development
of ﬂexible ontologies that embrace multiple
collections in one or more diseases. It therefore
facilitates the future aggregation of new or larger
resources. Such resources are precisely what
genetic epidemiology requires as it seeks to
unravel smaller effects. For example, a recent
genetic study on breast cancer was based on
50,000 patients and its authors (Easton et al.
2007) concluded: ‘‘The detection of further sus-
ceptibility loci will require genome-wide studies
with more complete coverage and using larger
numbers of cases and controls, together with the
combination of results across multiple studies.’’
• Secondary biobanking, through its focus on
resource management, is well placed to implement
the highest standards. This promotes research in a
neglected area. Standard methods research gets
low scores from funders compared with novel
methods research.
• When UDBN provides resource management for
new collections, the infrastructure cost is mar-
ginal. Hence, secondary biobanking is a more
efﬁcient use of ﬁnancial resources since it elim-
inates the requirement for separate primary bio-
banking infrastructure. These savings free up
funds allocated to genetic epidemiology for more
or larger investigations.
• The beneﬁts of a secondary biobank grow over
time through cost savings and synergies. There-
fore support for such an infrastructure should not
be based on short or medium term grants. This has
been recognised, for example, in the planned
development of the pan-European BBMRI bio-
banking system (Yuille et al. 2007) where the
intergovernmental European Strategy Forum on
Research Infrastructures recommends initial sup-
port for 10–20 years (European roadmap for
research infrastructures report 2006).
• A secondary biobank provides a useful way of
achieving public policy goals of research. Bio-
medical research must engage with the public to
maintain and build trust. It is unreasonable to
expect a primary biobank to work on this area.
However a secondary biobank is well placed to
undertake consent management, outreach work,
educational initiatives and public engagement
because, if it has a fair access policy, then it is
obliged to be proactive in being fair to patients.
UDBN has undertaken some educational initia-
tives (e.g. its Practical Biobanking courses held at
the University of Manchester) that start this
process.
• Could the UDBN model of secondary biobanking
be replicated in other jurisdictions? Could such
biobanks form a network? The identiﬁcation of
roadblocks in other jurisdictions to creating a
national secondary biobank is beyond the scope of
this review. However, the main practical issue is
whether national funders decide to adopt this
approach and then to impose the necessary grant
conditions. It should be noted that the primary
distinction between a secondary biobank and a
conventional primary biobank is policy-related:
an existing primary biobank can adopt the poli-
cies of a secondary biobank and thus function as
both simultaneously. An international network of
secondary biobanks is practical, even if national
laws prohibit sample and data export. A network
would only be curtailed by one jurisdiction
outlawing collaboration with scientists in another
jurisdiction. Few, if any, states do this.
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